Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Boston Scientific Corporation (NYSE:BSX)
by Jessica Moore · The Cerbat GemRepresentative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on January 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on December 24th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
- Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
- Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.
Boston Scientific Stock Performance
BSX stock traded down $0.97 during mid-day trading on Wednesday, hitting $93.17. 2,739,539 shares of the company were exchanged, compared to its average volume of 7,799,290. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The business has a 50 day simple moving average of $97.43 and a 200-day simple moving average of $100.58. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $138.11 billion, a PE ratio of 49.77, a price-to-earnings-growth ratio of 1.69 and a beta of 0.67.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.
Analysts Set New Price Targets
Several equities analysts have recently commented on the stock. Leerink Partners boosted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Citigroup restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Needham & Company LLC reissued a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a report on Friday, October 17th. Finally, Canaccord Genuity Group reduced their price target on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and an average target price of $125.21.
Check Out Our Latest Research Report on Boston Scientific
Institutional Trading of Boston Scientific
Institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its position in Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after buying an additional 3,932 shares during the last quarter. State Street Corp raised its holdings in shares of Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after purchasing an additional 713,379 shares during the last quarter. Synergy Asset Management LLC lifted its position in Boston Scientific by 3,493.0% during the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after purchasing an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC boosted its holdings in Boston Scientific by 39.5% in the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock worth $5,065,000 after purchasing an additional 14,700 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG grew its position in Boston Scientific by 75.3% in the 2nd quarter. Bank Pictet & Cie Europe AG now owns 164,654 shares of the medical equipment provider’s stock worth $17,685,000 after purchasing an additional 70,753 shares during the period. Institutional investors own 89.07% of the company’s stock.
Insider Activity
In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 93,095 shares of company stock valued at $9,305,450 in the last ninety days. 0.50% of the stock is currently owned by company insiders.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Boston Scientific Company Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.